Trial · NCT06561022
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0( Safety lead-in Phase) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 |
| Primary | objective response rate (ORR)( Safety lead-in Phase) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | objective response rate (ORR) |
| Primary | Progression-free survival (PFS)(Phase II) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | Progression-free survival (PFS) |
| Secondary | Overall survival (OS)(Phase II) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | Overall survival (OS) |
| Secondary | objective response rate (ORR)(Phase II) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | objective response rate (ORR) |
| Secondary | clinical benefit rate (CBR)(Phase II) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | clinical benefit rate (CBR) |
| Secondary | duration of response (DOR)(Phase II) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | duration of response (DOR) |
| Secondary | time to first response (TTR)(Phase II) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | time to first response (TTR) |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0(Phase II) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 |
| Secondary | Clinical benefit rate (CBR)( Safety lead-in Phase) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | Clinical benefit rate (CBR) |
| Secondary | Progression-free survival (PFS)( Safety lead-in Phase) | Baseline until disease progression or loss of clinical benefit, assessed up to 6 months | Progression-free survival (PFS) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06561022/registered